Rissardo J, Caprara A
Clin Pract. 2023; 13(6):1427-1448.
PMID: 37987429
PMC: 10660852.
DOI: 10.3390/clinpract13060128.
Huh Y, Caravaca J, Kim J, Cui Y, Huang Q, Gullberg G
Med Phys. 2023; 50(6):3726-3737.
PMID: 36916755
PMC: 10503418.
DOI: 10.1002/mp.16360.
Fahmi R, Platsch G, Bani Sadr A, Gouttard S, Thobois S, Zuehlsdorff S
Eur J Hybrid Imaging. 2021; 4(1):5.
PMID: 34191214
PMC: 8218096.
DOI: 10.1186/s41824-020-0074-2.
Buchert R, Buhmann C, Apostolova I, Meyer P, Gallinat J
Dtsch Arztebl Int. 2019; 116(44):747-754.
PMID: 31774054
PMC: 6912128.
DOI: 10.3238/arztebl.2019.0747.
Roussakis A, Piccini P, Politis M
Degener Neurol Neuromuscul Dis. 2019; 3:33-39.
PMID: 30890892
PMC: 6065574.
DOI: 10.2147/DNND.S19807.
Creation and validation of an I-123 FP-CIT template for statistical image analysis using high-resolution SPECT for parkinsonian patients.
Hida K, Nonokuma M, Kuwabara Y, Tani T, Takano K, Yoshimitsu K
Ann Nucl Med. 2016; 30(7):477-83.
PMID: 27225162
PMC: 4961732.
DOI: 10.1007/s12149-016-1085-8.
The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1.
Booth T, Nathan M, Waldman A, Quigley A, Schapira A, Buscombe J
AJNR Am J Neuroradiol. 2014; 36(2):229-35.
PMID: 24904053
PMC: 7965655.
DOI: 10.3174/ajnr.A3970.
Serotonin transporter availability in early stage Parkinson's disease and multiple system atrophy.
Suwijn S, Berendse H, Verschuur C, de Bie R, Booij J
ISRN Neurol. 2014; 2014:345132.
PMID: 24693450
PMC: 3945177.
DOI: 10.1155/2014/345132.
SERT-to-DAT ratios in early Parkinson's disease do not correlate with the development of dyskinesias.
Suwijn S, Berendse H, Verschuur C, Winogrodzka A, de Bie R, Booij J
EJNMMI Res. 2013; 3(1):44.
PMID: 23738774
PMC: 3680321.
DOI: 10.1186/2191-219X-3-44.
Synthesis and in vitro evaluation of novel nortropane derivatives as potential radiotracers for muscarinic m(2) receptors.
Knol R, van den Bos J, Janssen A, de Bruin K, van Eck-Smit B, Booij J
Int J Mol Imaging. 2011; 2011:709416.
PMID: 21755053
PMC: 3132655.
DOI: 10.1155/2011/709416.
Synthesis and Evaluation of Fluorinated Aporphines: Potential Positron Emission Tomography Ligands for D2 Receptors.
Sromek A, Si Y, Zhang T, George S, Seeman P, Neumeyer J
ACS Med Chem Lett. 2011; 2(3):189-194.
PMID: 21666830
PMC: 3110009.
DOI: 10.1021/ml1001689.
Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter.
Liu J, Zhu L, Plossl K, Lieberman B, Kung H
Bioorg Med Chem Lett. 2011; 21(10):2962-5.
PMID: 21458259
PMC: 3085641.
DOI: 10.1016/j.bmcl.2011.03.051.
Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.
Stehouwer J, Goodman M
PET Clin. 2010; 4(1):101-28.
PMID: 20216936
PMC: 2834529.
DOI: 10.1016/j.cpet.2009.05.006.
Comparison of 2beta-carbomethoxy-3beta-(4-[18F]fluorophenyl)tropane and N-(3-[18F]fluoropropyl)-2beta-carbomethoxy-3beta-(4-fluorophenyl)nortropane, tracers for imaging dopamine transporter in rat.
Marjamaki P, Haaparanta M, Forsback S, Fagerholm V, Eskola O, Gronroos T
Mol Imaging Biol. 2009; 12(3):269-77.
PMID: 19949983
DOI: 10.1007/s11307-009-0278-0.
Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs.
Booij J, Kemp P
Eur J Nucl Med Mol Imaging. 2007; 35(2):424-38.
PMID: 17968545
DOI: 10.1007/s00259-007-0621-0.
Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I.
Shetty H, Zoghbi S, Liow J, Ichise M, Hong J, Musachio J
Eur J Nucl Med Mol Imaging. 2006; 34(5):667-678.
PMID: 17096093
DOI: 10.1007/s00259-006-0277-1.
[(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain.
Halldin C, Erixon-Lindroth N, Pauli S, Chou Y, Okubo Y, Karlsson P
Eur J Nucl Med Mol Imaging. 2003; 30(9):1220-30.
PMID: 12811422
DOI: 10.1007/s00259-003-1212-3.
[99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent.
Kung M, Stevenson D, Plossl K, Meegalla S, BECKWITH A, Essman W
Eur J Nucl Med. 1997; 24(4):372-80.
PMID: 9096087
DOI: 10.1007/BF00881808.
[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
Booij J, Tissingh G, Boer G, Speelman J, Stoof J, Janssen A
J Neurol Neurosurg Psychiatry. 1997; 62(2):133-40.
PMID: 9048712
PMC: 486723.
DOI: 10.1136/jnnp.62.2.133.
Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease.
Booij J, Tissingh G, Winogrodzka A, Boer G, Stoof J, Wolters E
Eur J Nucl Med. 1997; 24(1):68-71.
PMID: 9044880
DOI: 10.1007/BF01728311.
